Examines E2F5 biomarker accuracy in prostate cancer diagnosis, indicating significant diagnostic potential.
exosomes/ml) and detection time within 30 min. Further, dielectrophoresis (DEP) enabled in situ exosome enrichment is integrated, enabling direct analysis of clinical samples without ultracentrifugation. Most importantly, the efficacy of E2F5 as an exosomal protein has been validated for accurate PC diagnosis in all patient cohorts. Multiple features have been extracted from the sensor response and analyzed using an ensemble classification method. Interestingly, the outcomes reveal that the sensor successfully distinguished BPH from HCs with appreciable accuracy of 91.11% and shows similar diagnostic performance with lower grade PC, higher grade PC, and healthy patients.
No takes yet. Share an insight, caveat, or question.
Mukherjee et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: